Former Executive Chairman and Chief Executive Officer (2) · Mirum Pharmaceuticals, Inc. (MIRM)

Michael Grey

A named executive officer of Mirum Pharmaceuticals in every fiscal year CompBrief holds from FY2018 to FY2019. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$5,662,396

Salary $300,000Stock awards $0Bonus $150,000

FY2018: $25,000

2nd of 4 named executive officers at Mirum Pharmaceuticals by FY2019 total.

4 named officers on file for Mirum Pharmaceuticals, FY2019

Michael Grey’s pay file — $29

  • 2 fiscal years of pay, line by line
  • MIRM’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Mirum Pharmaceuticals’s whole pay program stands against its peers

  • Mirum Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on MIRM→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed January 1, 1900 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Michael Grey’s full pay file as a PDF — free

More than this page: up to 10 years of Michael’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Michael Grey compensation by year

Mirum Pharmaceuticals Summary Compensation Table · all 2 fiscal years held
In US dollars, as Mirum Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019
Salary$25,000$300,000
Bonus$0$150,000
Stock awards$0$0
Option awards$0$5,212,396
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$0$0
Total$25,000$5,662,396

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Mirum Pharmaceuticals, Inc. DEF 14A filed January 1, 1900, accession 0001564590-20-019713, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Mirum Pharmaceuticals, Inc. filed document, accession 0001564590-20-019713. Every figure is read from that document and cited to the page and table it appears in. Filed January 1, 1900.

$25K
$5.7M
FY18
FY19
SalaryBonusOption awards

Equity holdings

unvested awards at FY2019 year-end
TypeUnvested unitsValue at year-endExercise price
Option262,500—$6.27
Option265,624—$2.94

Per the Outstanding Equity Awards at Fiscal Year-End table in Mirum Pharmaceuticals, Inc.'s FY2019 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

13 Form 4 lines since the FY2019 proxy (filed January 1, 1900)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-06-15Grant or award derivative—1,980$0.001,980
2026-06-15Grant or award derivative—3,772$0.003,772
2025-12-19Exercise or conversion10b5-150,000$2.9450,000
2025-12-19Sale10b5-150,000$78.000
2025-12-19Exercise or conversion derivative10b5-150,000$0.00181,176
2025-12-01Sale10b5-150,000$74.000
2025-12-01Exercise or conversion10b5-150,000$2.9450,000
2025-12-01Exercise or conversion derivative10b5-150,000$0.00231,176

The 8 most recent of 13 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Mirum Pharmaceuticals’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Christopher PeetzChief Executive Officer and President (4)$6,235,185
Michael Grey · this pageFormer Executive Chairman and Chief Executive Officer (2)$5,662,396
Pamela VigChief Scientific Officer (6)$2,681,958
Lara LongpreChief Development Officer (6)$2,526,658

Board service

Mirum Pharmaceuticals board · FY2021–FY2025
Director compensation in US dollars, as Mirum Pharmaceuticals reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$110,000$174,988$174,855—$459,843
FY2024$108,750$149,989$149,774—$408,513
FY2023$105,000—$346,747—$451,747
FY2022$103,750—$278,299—$382,049
FY2021$100,000—$197,379—$297,379

Each year as the company reported it in Mirum Pharmaceuticals's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Mirum Pharmaceuticals pays directors a $50,000 cash retainer and $300,000 in equity. As stated in Mirum Pharmaceuticals's FY2025 proxy.

Committees

Chairman of the Board (Chair)

The full Mirum Pharmaceuticals compensation record

free company brief

This page is one person within Mirum Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Mirum Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Mirum Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Michael Grey's compensation dossier · One-time report. No refunds.